GC-REAAD™ ITIH3 ELISA Assay
The GC-REAAD™ ITIH3 ELISA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: 0.4 RU
Standard Range: 0.4-0.7 RU
Incubation Time: 1.25 hours
Sample Type: Serum, plasma
Sample Size: 100 µl
Alternative Names: Inter-alpha-trypsin inhibitor heavy chain 3, ITIH3 Protein, Human ITIH3, hITIH3, Gastric Carcinoma REAAD
Gastric Carcinoma (GC) is the fifth most common cancer malignancy in the world with more than 70% of cases occur in developing countries, and half the world total occurs in Eastern Asia [3,5,6]. GC is the third leading cause of cancer death worldwide. The highest estimated mortality rates are in Eastern Asia. High mortality rates are also present in Central and Eastern Europe, and in Central and South America. The level of ITIH3 proteins has been found to be closely associated with Gastric Carcinoma. Higher levels of ITIH3 proteins were detected in plasma of patients with gastric carcinoma (both early and late) as compared to plasma of non-carcinoma patients [1,2,4].
GC-REAAD™ sandwich ELISA uses two layers of antibodies (i.e. capture and detection antibody) targeting at two different antigenic epitopes expressed by human ITIH3 proteins capable of binding to the respective antibody to semi-quantify the level of human ITIH3 protein. The test uses an arbitrary unit of measurement known as REAAD™-units (RU) which is used for determining the patients’ GC risk level.
GC-REAAD™ is useful for the semi-quantification of human ITIH3 proteins in patients. All data from these assays, however at best offer supplementary information to clinicians and act as an aid to diagnosis only. It is therefore important that a diagnosis is made in conjunction with other recommended clinical investigations.